UniQure N.V. (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

UniQure N.V. (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

UniQure N.V. (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
UniQure N.V. (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 23, 2016
44 pages — Published Sep 23, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

UniQure N.V. (UniQure) formerly uniQure B.V. is a pharmaceutical company that develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies by using its modular technology platform. Its glybera is used to restore the LPL enzyme activity. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia B, sanfilippo B syndrome, acute intermittent porphyria, congestive heart failure and Parkinsons disease. UniQure is also developing gene therapies for cardiovascular diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions.

UniQure N.V. (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

  
Source:
Document ID
GDPH389133D
Country
Industry
Ticker
QURE=NL
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
UniQure N.V., Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201652
UniQure N.V., Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201671
UniQure N.V., Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201681
UniQure N.V., Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201691
UniQure N.V., Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016102
UniQure N.V., Pharmaceuticals &Healthcare, Deal Details1229
  Venture Financing121
    uniQure Raises Additional USD10 Million in Venture Debt Financing121
    uniQure Raises US$10 Million In Venture Financing131
    UniQure Raises USD17.5 Million in Venture Financing142
  Partnerships161
    Bristol-Myers Squibb Enters into Agreement with uniQure162
    Synpromics Expands Co-Development Agreement with uniQure for Gene Therapy Vector181
    uniQure Enters Into Co-Marketing Agreement With Chiesi Farmaceutici192
    uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease212
    Amsterdam Molecular Therapeutics Enters Into An Agreement With Institut Pasteur And The Consortium231
  Licensing Agreements241
    uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics241
    uniQure Enters into Licensing Agreement with Protein Sciences251
    Treeway Enters into Licensing Agreement with uniQure261
    uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology271
    Benitec Biopharma Enters Into Licenising Agreement With uniQure281
    uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology291
    Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health301
    Amsterdam Molecular Enters Into Licensing Agreement With National Institutes Of Health311
  Equity Offering321
    uniQure Raises USD38 Million in Private Placement of Shares321
    uniQure Raises USD88.5 Million in Public Offering of Shares332
    uniQure Completes IPO For US$91.8 Million352
    uniQure Announces Private Placement Of Shares For US$7.8 Million371
  Acquisition381
    UniQure Acquires InoCard for USD4 Million381
    uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy392
UniQure N.V. - Key Competitors411
Key Employees421
Locations And Subsidiaries431
  Head Office431
  Other Locations &Subsidiaries431
Appendix441
  Methodology441
  About GlobalData441
  Contact Us441
  Disclaimer441

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "UniQure N.V. (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 23, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/UniQure-N-V-QURE-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6700>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). UniQure N.V. (QURE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 23, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/UniQure-N-V-QURE-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6700>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research